<DOC>
	<DOCNO>NCT02128893</DOCNO>
	<brief_summary>The purpose study assess effect multiple dose esomeprazole pharmacokinetics isavuconazole . In addition , safety tolerability isavuconazole alone combination esomeprazole assess</brief_summary>
	<brief_title>A Study Evaluate Effect Multiple Doses Esomeprazole Pharmacokinetics Isavuconazole</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>The subject body weight least 50 kg body mass index 18.5 32 kg/m2 , inclusive The subject 's 12lead electrocardiogram ( ECG ) normal The subject 's clinical laboratory test result within normal limit The subject history evidence clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy The subject history bowel obstruction , swallow disorder , severe gastrointestinal disorder , major gastrointestinal surgery , gastric/duodenal ulcer condition may interfere study drug absorption Female subject pregnant within 6 month screen breast feeding within 3 month screen The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history either Short Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) . QT time start Q wave end T wave heart 's electrical system The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic admission The subject receive vaccination within last 30 day prior study drug administration The subject positive serology test Hepatitis B surface antigen ( HBsAg ) , Hepatitis A Immunoglobulin M antibody ( anti HAV ( IgM ) ) , Hepatitis C antibody ( antiHCV ) , human immunodeficiency virus ( antiHIV 1+2 ) The subject know suspect allergy component trial product azole class compound , history multiple and/or severe allergy drug food , history severe anaphylactic reaction The subject use tobacco nicotine containing product last 6 month The subject treatment prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior exception hormonal method contraception , hormone replacement therapy , occasional use acetaminophen 2 g/day The subject participate interventional clinical study receive investigational drug within past 30 day 5 halflives , whichever long The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission The subject anticipate inability abstain alcohol caffeine use 48 hour prior throughout duration study ; grapefruit , grapefruit juice , star fruit , Seville oranges product contain item 72 hour prior throughout duration study The subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical/substance abuse within past 2 year prior screen ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor ) subject test positive alcohol drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) The subject take part strenuous exercise within 3 day Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>Esomeprazole</keyword>
	<keyword>BAL4815</keyword>
	<keyword>BAL8728</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>